Register for our free email digests:
Juno Therapeutics Inc.
Division of Bristol-Myers Squibb Co.
www.junotherapeutics.com
Latest From Juno Therapeutics Inc.
Stockwatch: Gilead, BMS Expose High Cost Of M&A
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.
Gene Therapy Approvals By US FDA Could Double In 2020
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
Finance Watch: Omega, Perceptive/Xontogeny Raise $648m For Life Science Investments
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
-
Hans Bishop, Pres. & CEO
Steven D Harr, MD, Head, Corp. Dev. & CFO
Hyam I Levitsky, MD, EVP, CSO
Sunil Agarwal, MD, Pres., R&D - Contact Info
-
Juno Therapeutics Inc.
Phone: (206) 582-1600
400 Dexter Ave. North
Ste. 1200
Seattle, WA 98109
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice